Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity

Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy

(2014) Liat Binyamin et al.   JOURNAL OF IMMUNOLOGY

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

(2012) U. Bacher et al.   BLOOD

Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells

(2012) S. Gill et al.   BLOOD

Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor

(2012) Christiane Sahm et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Natural killer cells: a review of manufacturing and clinical utility

(2012) Scott A. Koepsell et al.   TRANSFUSION

Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions

(2012) Hans Klingemann et al.   TRANSFUSION

Tumor Induced Inactivation of Natural Killer Cell Cytotoxic Function; Implication in Growth, Expansion and Differentiation of Cancer Stem Cells

(2012) Anahid Jewett et al.   Journal of Cancer

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

(2011) I. N. M. Micallef et al.   BLOOD

Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor

(2011) D V Tassev et al.   CANCER GENE THERAPY

Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression

(2011) M. R. Parkhurst et al.   CLINICAL CANCER RESEARCH

Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

(2011) Carlos A Ramos et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity

(2011) Kory L. Alderson et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin

(2011) Ruth Esser et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens

(2011) Laurent Boissel et al.   LEUKEMIA & LYMPHOMA

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natural killer cells and cancer: Regulation by the killer cell Ig-like receptors (KIR)

(2010) Amanda K. Purdy et al.   CANCER BIOLOGY & THERAPY

Ex-vivo expansion of NK cells: What is the priority - high yield or high purity?

(2010) Maria Berg et al.   CYTOTHERAPY

Variable Contribution of Monoclonal Antibodies to ADCC in patients with chronic lymphocytic leukemia

(2009) James Weitzman et al.   LEUKEMIA & LYMPHOMA

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

(2008) S. Arai et al.   CYTOTHERAPY